Enanta Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Enanta Pharmaceuticals's estimated annual revenue is currently $39.4M per year.
- Enanta Pharmaceuticals received $20.0M in venture funding in September 2004.
- Enanta Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Enanta Pharmaceuticals has 196 Employees.
- Enanta Pharmaceuticals grew their employee count by 1% last year.
Enanta Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Chief Legal Officer | Reveal Email/Phone |
3 | Executive Director Accounting, Controller | Reveal Email/Phone |
4 | VP Chemistry | Reveal Email/Phone |
5 | SVP and General Counsel | Reveal Email/Phone |
6 | VP, DMPK & Bioanalysis | Reveal Email/Phone |
7 | VP Finance | Reveal Email/Phone |
8 | VP, Clinical Pharmacology | Reveal Email/Phone |
9 | SVP, New Product Strategy and Development | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
Enanta Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Enanta Pharmaceuticals?
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta's collaboration with AbbVie, have now been approved around the world as part of AbbVie's regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta's research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.
keywords:Biotechnology,Healthcare,Pharmaceuticals
N/A
Total Funding
196
Number of Employees
$39.4M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Enanta Pharmaceuticals News
Analysts Expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Will Post Quarterly Sales of $20.40 Million. Posted by admin on Apr 14th, 2022.
Enanta Pharmaceuticals posted earnings per share of ($1.09) during the same quarter last year, which would indicate a negative year-over-year...
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of...
Other Companies in Watertown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $43M | 217 | N/A | N/A |
#2 | $79.1M | 218 | 8% | N/A |
#3 | $15M | 230 | 11% | N/A |
#4 | $63.8M | 231 | 5% | N/A |
#5 | $66.3M | 240 | 2% | N/A |
Enanta Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-06-13 | $18.0M | Lead Investor: BioVe | Biomedicine LP | Article |
| 2004-01-15 | $12.0M | Lead Investor: Multi | Article | |
| 2004-09-01 | $20.0M | Undisclosed | Shionogi and Co, Techno Venture Management | Article |